Phoenix 24
The body is also a political territory.
London, April 2026. Testosterone therapy is gaining ground as an option for some menopausal women, especially in cases linked to persistent low sexual desire, fatigue and reduced vitality after other causes have been evaluated. The shift reflects a broader change in how menopause is being discussed: less as a silent decline and more as a clinical, social and quality-of-life issue requiring individualized care.
The key point is caution. International guidance does not frame testosterone as a universal anti-aging treatment, a general energy booster or a cosmetic hormone. Its strongest evidence-based indication remains hypoactive sexual desire disorder in postmenopausal women, particularly when symptoms cause distress and are not better explained by relationship, psychological, medication-related or other medical factors.
This distinction matters because hormone therapy sits at the intersection of science, regulation, gender and market pressure. Many women report that their symptoms are minimized or fragmented across consultations, while wellness industries often turn hormonal discomfort into a commercial promise. Between medical neglect and overmarketing, testosterone has entered a sensitive space where precision is essential.
Specialists emphasize that treatment requires proper assessment, appropriate dosing and medical follow-up. Women’s testosterone levels are much lower than men’s, and excessive dosing can produce unwanted effects such as acne, hair growth, voice changes or other androgenic symptoms. The issue is not whether testosterone can help some patients; it is whether it is prescribed with discipline rather than enthusiasm.
The debate also exposes an older blind spot in medicine. Menopause has long been treated as a private inconvenience rather than a major transition affecting work, sexuality, mental health, relationships and identity. The growing discussion around testosterone signals that women are demanding more complete clinical answers, not just reassurance that discomfort is normal.
Testosterone will not define menopause care by itself. But its rise shows that the conversation is moving beyond stigma and silence. The next challenge is to protect women from both undertreatment and hormonal simplification, because dignity in medicine begins when symptoms are heard without turning every treatment into a trend.
Behind every fact, there is intent. Behind every silence, a structure.